Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpiN-Tec MCTI UFMG COVID-19 booster vaccine phase 1/2 study
RBR-3f598cjPhase 2Recruiting
- Sponsor
- CT Vacinas
- Start
- Nov 2022
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of SpiN-Tec and ChAdOx1 nCoV-19, sponsored by CT Vacinas. Started Nov 2022; status: recruiting.
02
Drugs
SpiN-TecChAdOx1 nCoV-19
Beyond the preview
Go deeper on RBR-3f598cj.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3f598cj.